Helsinki-based Switchpoint Bio Raises €4.75 Million to Develop Blood-Based Epigenomic Platform for Drug Development
Switchpoint Bio, a Helsinki‑based TechBio startup, emerged from stealth and secured €4.75 million in pre‑seed funding led by Treehouse Delmar Investments to advance its blood‑based epigenomic platform that aims to give drug developers a scalable view of disease and treatment effects.